biostudies-literatureCallesen LBKræftens BekæmpelseThe Danish Cancer SocietyHealth Research Foundation of Central Denmark Region, grant no. A1602500-513https://www.ebi.ac.uk/biostudies/studies/S-EPMC9345951biostudies-literatureUnknown127(3)<h4>Background</h4>We investigate the current knowledge on circulating tumour DNA (ctDNA) and its clinical utility in predicting outcomes in patients with metastatic colorectal cancer (mCRC).<h4>Methods</h4>PubMed, Embase, Cochrane Database of Systematic Reviews and Cochrane Central Register of Controlled Trials were searched. Last search 16/12/2020. We included studies on patients with mCRC reporting the predictive or prognostic value of ctDNA. We performed separate random-effects meta-analyses to investigate if baseline ctDNA and early changes in ctDNA levels during treatment were associated with survival. The risk of bias was assessed according to the Quality in Prognosis Studies tool.<h4>Results</h4>Seventy-one studies were included with 6930 patients. Twenty-four studies were includedBritish journal of cancerCirculating tumour DNA and its clinical utility in predicting treatment response or survival in patients with metastatic colorectal cancer: a systematic review and meta-analysis.PMC9345951R257-A14700Callesen LBBoysen AKHamfjord JPallisgaard NKure EHGuren TKSpindler KGfalseCirculating tumour DNA and its clinical utility in predicting treatment response or survival in patients with metastatic colorectal cancer: a systematic review and meta-analysis.<h4>Background</h4>We investigate the current knowledge on circulating tumour DNA (ctDNA) and its clinical utility in predicting outcomes in patients with metastatic colorectal cancer (mCRC).<h4>Methods</h4>PubMed, Embase, Cochrane Database of Systematic Reviews and Cochrane Central Register of Controlled Trials were searched. Last search 16/12/2020. We included studies on patients with mCRC reporting the predictive or prognostic value of ctDNA. We performed separate random-effects meta-analyses to investigate if baseline ctDNA and early changes in ctDNA levels during treatment were associated with survival. The risk of bias was assessed according to the Quality in Prognosis Studies tool.<h4>Results</h4>Seventy-one studies were included with 6930 patients. Twenty-four studies were included2022-01-01T00:00:00Z2022 Aug2025-04-04T08:28:28.349Z2024-12-04T08:54:18.984ZS-EPMC93459513544066610.1038/s41416-022-01816-4